1. Koh E, Ueda Y, Nakamura T, Kobayashi A, Katsuta S, Takahashi H. Apoptosis in young rats with adriamycin-induced cardiomyopathy—comparison with pirarubicin, a new anthracycline derivative. Pediatr Res. 2002;51(2):256–9.
2. Zheng S, Zhou S, Qiao G, Yang Q, Zhang Z, Lin F, et al. Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma. Am J Cancer Res. 2015;5(1):411.
3. Mizutani H, Hotta S, Nishimoto A, Ikemura K, Miyazawa D, Ikeda Y, et al. Pirarubicin, an anthracycline anticancer agent, induces apoptosis through generation of hydrogen peroxide. Anticancer Res. 2017;37(11):6063–9.
4. Kunimoto S, Miura K, Takahashi Y, Takeuchi T, Umezawa H. Rapid uptake by cultured tumor cells and intracellular behavior of 4'-O-tetrahydropyranyladriamycin. The Journal of antibiotics. 1983;36(3):312–7.
5. Kunimoto S, Miura K, Umezawa K, Xu C-Z, Masuda T, Takeuchi T, et al. Cellular uptake and efflux and cytostatic activity of 4'-O-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor cell lines. The Journal of Antibiotics. 1984;37(12):1697–702.